Moreover, mTOR inhibition mitigated p53 activation induced by UA-and-UVR combined treatment, in both RPE and skin melanoma cells, but specifically sustained the NF-κB activation in the latter cell line [18]. The gene discussed is NFKB1; the disease is cutaneous melanoma.